ArticleCancers2021

Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.

Gabrielle van Caloen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.